ima402
immatics
['ima402', 'immatics ']
we announced comprehensive preclinical data for our #tcer candidate, ima402, targeting prame congress 2022. ima402 is the 2nd program from our tcr bispecifics pipeline with a format that is optimized for enhanced anti-tumor activity &amp; safety. 
Immatics is active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer
Legal notice: https://t.co/15aK63mHYH
#immaticsjobs